REAL-WORLD EFFICACY OF DOLUTEGRAVIR: A REVIEW OF VIROLOGICAL SUPPRESSION AND CD4+ RECOVERY TRENDS
American Journal of Medical and Natural Sciences · 18.02.2026 · 7-15
DOI: 10.70604/journal.v7i1.24 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical and Natural Sciences, online erschienen am 18.02.2026. Verfasst von Sribharathi Y. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Since its recommendation by the World Health Organization as a preferred first-line agent, Dolutegravir (DTG) has transformed HIV management due to its high genetic barrier to resistance and superior tolerability. While clinical trials have established its efficacy, there is a critical need for real-world validation of its impact on primary clinical markers during the early stages of treatment. This review evaluates the effectiveness of DTG-based antiretroviral therapy (ART) on virological outcomes and immunological recovery within the first six months of initiation.
Methods
A comprehensive review of prospective and retrospective clinical data was conducted, focusing on HIV-1 infected adults (\ge18 years) initiating DTG-based regimens. The primary endpoints assessed were the rate of virological suppression (defined as HIV-1 RNA
Zitieren
APA
Y, S. (2026). REAL-WORLD EFFICACY OF DOLUTEGRAVIR: A REVIEW OF VIROLOGICAL SUPPRESSION AND CD4+ RECOVERY TRENDS. American Journal of Medical and Natural Sciences, 7-15. https://doi.org/10.70604/journal.v7i1.24
Vancouver
Y S. REAL-WORLD EFFICACY OF DOLUTEGRAVIR: A REVIEW OF VIROLOGICAL SUPPRESSION AND CD4+ RECOVERY TRENDS. American Journal of Medical and Natural Sciences. 2026:7-15. doi:10.70604/journal.v7i1.24
BibTeX
@article{Y2026,
author = {Y, Sribharathi},
title = {REAL-WORLD EFFICACY OF DOLUTEGRAVIR: A REVIEW OF VIROLOGICAL SUPPRESSION AND CD4+ RECOVERY TRENDS},
journal = {American Journal of Medical and Natural Sciences},
year = {2026},
pages = {7--15},
doi = {10.70604/journal.v7i1.24}
}
EUVIMED